Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma

MH Kulke¹, RD Odze², KS Thakore¹, G Thomas¹, H Wang³, M Loda¹,² and C Eng⁴

¹Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston MA; ²Department of Pathology, Brigham and Women’s Hospital, and Harvard Medical School, Boston MA; ³Department of Pathology, Beth-Israel-Deaconess Medical Center and Harvard Medical School, Boston MA; ⁴Human Cancer Genetics Program, Ohio State University, Columbus, Ohio, and CRC Human Cancer Genetics Research Group, University of Cambridge, Cambridge, UK

Summary PTEN is a putative tumour suppressor gene located on chromosome band 10q23. Mutations in PTEN have been identified in numerous human malignancies, including cancers of the brain, endometrium, ovary, and prostate. In this study, we screened 80 Barrett’s oesophagus-associated adenocarcinomas (BOAd) for loss of heterozygosity (LOH) at 10q23, using the microsatellite markers D10S541, D10S521, and D10S551. Tumours demonstrating LOH were then screened for the presence or absence of PTEN mutations. LOH at one or more loci was identified in 17/80 (21%) cases. In none of these cases did we detect mutations in PTEN. The presence of LOH did not correlate with patient age, tumour stage, degree of differentiation, presence of perineural or vascular invasion, or overall survival. We conclude that LOH at chromosome 10q23 is uncommon in BOAd, is not associated with mutations in the PTEN tumour suppressor gene, and does not correlate with the clinical or pathologic features of these tumours. It is possible that PTEN is inactivated through other mechanisms in BOAd. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: PTEN; Barrett’s oesophagus; oesophageal adenocarcinoma; 10q23

In North America, the incidence of oesophageal adenocarcinoma is increasing at a rate higher than any other malignancy (Blot et al, 1991). The development of oesophageal adenocarcinoma is related to chronic gastro-oesophageal reflux and the subsequent development of Barrett’s oesophagus (Lagergren et al, 1999). However, the molecular events leading to the development of oesophageal adenocarcinoma remain poorly understood.

Loss of tumour suppressor gene function may play a role in the development of oesophageal adenocarcinoma. Alleloype analysis of oesophageal adenocarcinoma specimens has revealed frequent loss of heterozygosity (LOH) at several sites of known tumour suppressor genes. These sites include 17p (p53), 18q (DCC); 9p21 (CDKN2/p16), and 5q (APC) (Huang et al, 1992; Hammoud et al, 1996; Dolan et al, 1998). PTEN has recently been identified as a novel tumour suppressor gene that is deleted or mutated in a wide range of human malignancies (Li et al, 1997; Steck et al, 1997). PTEN is located on chromosome band 10q23, and encodes a 403 amino acid dual specificity phosphatase that contains regions of homology to tensin and auxillin, cytoskeletal proteins that interact with adhesion molecules (Myers et al, 1997). Germline mutations of PTEN have been found in Cowden syndrome, an autosomal dominant inherited cancer syndrome characterized by hamartomas of the skin, intestine, breast and thyroid, and associated with a high risk of breast and thyroid cancers (Liaw et al, 1997). Germline mutations in PTEN have also been found in Bannayan-Zonana syndrome, which is characterized by intestinal hamartomatous polyps, lipomatosis, macrocephaly, and speckled penis, as well as in a Proteus-like syndrome (Marsh et al, 1997a, 1999; Zhou et al, 2000).

Somatic mutations of PTEN have been found in sporadic tumours of the breast (Teng et al, 1997; Chen et al, 1999; Freihoff et al, 1999), thyroid (Dahia et al, 1997), head and neck (Okami et al, 1998; Shao et al, 1998), central nervous system (Liu et al, 1997; Rasheed et al, 1997; Teng et al, 1997; Wang et al, 1997; Bostrom et al, 1998; Chiarionello et al, 1998; Duerr et al, 1998; Maier et al, 1998; Davies et al, 1999; Zhou et al, 1999), endometrium (Kong et al, 1997; Risinger et al, 1997; Tashiro et al, 1997; Simpkins et al, 1998; Mutter et al, 2000; Yaginuma et al, 2000), ovary (Tashiro et al, 1997; Teng et al, 1997; Obata et al, 1998; Saito et al, 2000), prostate (Cairns et al, 1997; Dong et al, 1998; Gray et al, 1998; Pesche et al, 1998; Suzuki et al, 1998; Feilotter et al, 1999), kidney (Teng et al, 1997; Alimov et al, 1999), lung (Kohno et al, 1998; Yokomizo et al, 1998), and in melanomas (Teng et al, 1997; Tsao et al, 1998) and non-Hodgkin lymphomas (Gronbaek et al, 1998; Nakahara et al, 1998; Sakai et al, 1998; Butler et al, 1999; Dahia et al, 1999). Whether loss of PTEN function plays a role in the development of Barrett’s oesophagus-associated adenocarcinoma (BOAd) is not known. In this study, we determined the prevalence and clinical significance of LOH at 10q23 in 80 cases of BOAd. Tumours demonstrating LOH were screened for PTEN mutations to determine if PTEN inactivation plays a role in the development of this type of malignancy.
MATERIALS AND METHODS

Study group

80 patients who had en bloc oesophageal resection at the Brigham and Women’s Hospital and at the Beth Israel-Deaconess Hospital between 1973 and 1995 were identified. All patients had histologically confirmed BOAd, and none had received preoperative chemotherapy or radiation. All patients were treated surgically with an intent to cure.

Selected clinical information (patient age, gender) and follow-up data were obtained from review of the patient’s hospital charts and the hospital tumour registry, or from direct telephone interviews with the patient and/or his/her family when necessary. Follow-up time was calculated from the date of initial diagnosis to either the date of death or, for the patients who were still alive, to the date of the most recent clinical investigation. In the survival analysis, either death or tumour recurrence was considered a failure event. Patients alive without disease at last follow-up were censored in the analysis.

Pathologic analysis

All oesophageal resection specimens were received in the surgical pathology laboratory in the fresh state and fixed in 10% buffered formalin for subsequent tissue sectioning. Tissue sections were processed routinely, embedded in paraffin, and stained with haematoxylin and eosin (H & E).

The following microscopic features were evaluated in all cases by one of the authors (RDO): 1) Pathologic stage according to the 1993 revised AJCC TNM classification (Fleming et al, 1997); 2) The presence or absence of lymphovascular invasion; 3) The presence or absence of perineural invasion; 4) Degree of tumour differentiation (well, > 95% of the tumour composed of glands; moderate, 50–95% of the tumour composed of glands; poor, < 50% of the tumour composed of glands).

Molecular analysis

Sections from paraffin-embedded tumour specimens were cut. Tumour and normal tissue were identified and separated by microdissection. DNA extraction was performed using the QIAprep kit (Qiagen Inc, Chatsworth, CA). PCR amplification was performed using primers for 3 known microsatellite repeat sequences: D10S219, D10S541, and D10S551. PCR primers were 5’ tagged with fluorescent dye labels. PCR products were then electrophoresed on 6% denaturing polyacrylamide gels and results were analysed using GeneScan 672 collection and analysis software (Genescan, Applied Biosystems, Foster City CA). Loss of one PTEN allele was established when the normal:tumour DNA peak ratio was greater than 1.5:1.

All cases demonstrating LOH were analysed further with denaturing-gradient gel electrophoresis (DGGE). In these cases, DGGE was completed for all nine exons of PTEN. GC-clamped primers for each exon have been previously described (Guldberg et al, 1997; Marsh et al, 1997a, 1998). PCR products were generated using the following conditions: a ‘hot start’ at 95°C for 10 min; followed by 40 cycles of 94°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min; followed by 72°C for 10 min. Heteroduplexing of PCR products was performed with one cycle of 98°C for 8 min, 55°C for 30 min, and 40°C for 30 min. PCR was performed in 1X PCR buffer (Life Technologies Inc.) 0.4 μM primer (Life Technologies, Inc. and 2.5 units of Taq polymerase (Life Technologies, Inc) with TaqStart antibody (Clontech, Palo Alto, CA). PCR products were separated on 1 mm 10% polyacrylamide gels with a gradient of 15–20% urea and 0–10% glycerol. Gels were run at 100 V for 16 h at 60°C.

Cases in which the DGGE analysis was not definitive were sequenced directly. In these cases, the exon in question was sequenced using nested primers designed within the flanking intronic sequences. PCR conditions and primers for sequencing were previously described (Liaw et al, 1997; Marsh et al, 1997b; Steck et al, 1997).

Statistical analysis

The data analysis was done with STATA statistical software (STATA Corporation, College Station, Texas). Comparison of categorical data was done with either chi-square or Fisher’s exact test, depending on sample size. Comparison for numeric data was done with the t-test. Survival analysis for clinical and pathologic variables was performed using a log-rank test. All variables that were statistically significant by univariate analysis ($P < 0.05$) were also evaluated by multivariate analysis. Kaplan–Meier curves were determined for selected groups of patients for comparison of survival.

RESULTS

A total of 80 BOAd specimens were analysed. Of the 80 samples, 63 had pathologic and clinical follow-up data. The demographic and pathologic features of the patients are summarized in Table 1. Patients had a mean age of 62 years and were predominantly male (M:F = 8:1). The mean follow-up time was 33 months. At the time of last evaluation, 22 (35%) were alive and disease-free, 1 (2%) was alive with disease, and 39 (62%) had died of disease. All stages of disease were represented in the group: 12 (19%) patients had stage I, 14 (22%) stage IIA, 9 (14%) stage IIB, 24 (38%) stage III, and 4 (6%) stage IV lesions.

Table 1: Demographic and pathologic features of the patient population

| Characteristic | No. of patients |
|---------------|----------------|
| Number of patients | 80 |
| Mean age (years) | 62 (37–87) |
| Male:female ratio | 8:1 (56:7) |
| Follow-up (months) | 33 (1–204) |
| Survival status | |
| Alive without disease | 22 (35%) |
| Alive with disease | 1 (2%) |
| Dead of disease | 39 (62%) |
| Dead of other causes | 1 (2%) |
| Pathologic stage | |
| I | 12 (19%) |
| IIA | 14 (22%) |
| IIB | 9 (14%) |
| III | 24 (38%) |
| IV | 4 (6%) |
| Tumour differentiation | |
| Well-differentiated | 4 (7%) |
| Moderately differentiated | 32 (55%) |
| Poorly differentiated | 22 (38%) |
| Perineural invasion | 16 (25%) |
| Vascular invasion | 25 (40%) |

© 2001 Cancer Research Campaign
80 samples were analysed for evidence of LOH at 10q23. A panel of loci was initially evaluated in DNA extracted from the paraffin-embedded samples. We found that several of these markers, including AFM086, a polymorphic marker within the PTEN gene, did not yield reproducible results in the archival specimens. 3 microsatellite loci (D10S219, D10S541 and D10S551) were selected for further study based on their reproducibility in our specimens and on their location flanking the PTEN tumour suppressor gene (Figure 1). Of the 3 markers, D10S541 is telomeric and in closest proximity to PTEN (< 0.3 cM) whereas D10S219 and D10S551 are centromeric and more distant from the gene (9 cM and 6 cM, respectively). A representative example of LOH is shown in Figure 2. All but one case were evaluable for LOH with at least one microsatellite marker (Figure 3). LOH was found most commonly at the D10S541 locus (11/70; 15.7%) and less commonly at D10S219 (4/74; 5.4%) and D10S551 (4/76; 5.2%). In almost all cases, LOH was found at only one of 3 loci examined. In 2 cases, LOH was noted at 2 loci. The first (#31) demonstrated LOH at both D10S219 and D10S551, and the second (#55) demonstrated LOH at D10S219 and D10S541. In no cases did all 3 loci demonstrate LOH. The total prevalence of LOH at one or more loci was 17/80 (21%).

DGGE was performed on all cases demonstrating LOH to determine if PTEN mutations were present in the remaining allele. All 9 exons of PTEN were analysed. In all but 9 cases, DGGE analysis demonstrated no evidence of PTEN mutations. In these 9 cases, the results of DGGE were not interpretable, and direct sequencing of the PTEN exon in question was performed. In none of these cases were mutations in PTEN found.

No relationship was found between the presence of LOH at 10q23 and patient age (P = 0.98), degree of tumour differentiation (P = 0.58), tumour stage (P = 0.43), presence of perineural invasion (P = 0.32), or the presence of vascular invasion (P = 0.37). There was no correlation between the presence of LOH and overall survival (P = 0.63).

**DISCUSSION**

An analysis of 80 cases of BOAd demonstrated LOH at chromosome 10q23 in 21% of cases. LOH was found most commonly with the microsatellite locus D10S541, which is only several hundred Kb from PTEN, and less commonly at the microsatellite loci D10S219 and D10S551 (Figure 1). A representative example of LOH is shown in Figure 2. All but one case were evaluable for LOH with at least one microsatellite marker (Figure 3). LOH was found most commonly at the D10S541 locus (11/70; 15.7%) and less commonly at D10S219 (4/74; 5.4%) and D10S551 (4/76; 5.2%). In almost all cases, LOH was found at only one of 3 loci examined. In 2 cases, LOH was noted at 2 loci. The first (#31) demonstrated LOH at both D10S219 and D10S551, and the second (#55) demonstrated LOH at D10S219 and D10S541. In no cases did all 3 loci demonstrate LOH. The total prevalence of LOH at one or more loci was 17/80 (21%).

DGGE was performed on all cases demonstrating LOH to determine if PTEN mutations were present in the remaining allele. All 9 exons of PTEN were analysed. In all but 9 cases, DGGE analysis demonstrated no evidence of PTEN mutations. In these 9 cases, the results of DGGE were not interpretable, and direct sequencing of the PTEN exon in question was performed. In none of these cases were mutations in PTEN found.

No relationship was found between the presence of LOH at 10q23 and patient age (P = 0.98), degree of tumour differentiation (P = 0.58), tumour stage (P = 0.43), presence of perineural invasion (P = 0.32), or the presence of vascular invasion (P = 0.37). There was no correlation between the presence of LOH and overall survival (P = 0.63).
markers D10S219 and D10S551, which are more distant from the PTEN locus. Studies of the 10q23 region in other malignancies have also noted a higher rate of LOH at the D10S541 locus, leading to speculation that loss of this marker correlates closely with loss of PTEN. In an analysis of sporadic breast cancers using 11 microsatellite markers, LOH at D10S541 was found more commonly than with any other marker, and occurred in 55% of cases (Singh et al, 1998a).

To assess if biallelic structural defects of PTEN play a role in the development of oesophageal adenocarcinoma, we screened all 17 cases that demonstrated LOH for PTEN mutations using DGGE and, when necessary, direct sequence analysis. In no case did we find evidence of PTEN mutations in the respective remaining allele. The finding of 10q23 LOH without associated PTEN mutations is not unprecedented. Both 10q23 LOH and somatic PTEN mutations have been demonstrated in endometrial carcinomas (Kong et al, 1997; Mutter et al, 2000), endometrioid ovarian carcinoma (Teng et al, 1997; Obata et al, 1998; Saito et al, 2000), and high-grade gliomas (Teng et al, 1997; Wang et al, 1997; Bostrom et al, 1998; Chiarello et al, 1998; Zhou et al, 1999). However, despite the presence of 10q23 LOH, somatic mutations of PTEN are either absent or exceedingly rare in primary cancers of the pancreas (Okami et al, 1998), kidney (Teng et al, 1997; Alimov et al, 1999), bladder (Cairns et al, 1998; Aveyard et al, 1999), prostate (Cairns et al, 1997; Feilotter et al, 1998; Pesche et al, 1998; Suzuki et al, 1998), breast (Feilotter et al, 1999; Freihoff et al, 1999), thyroid (Dahia et al, 1997), head and neck (Shao et al, 1998; Gasparotto et al, 1999; Okami et al, 1998), and lung (Okami et al, 1998; Petersen et al, 1998).

Several investigators have suggested that the lack of PTEN mutations in these malignancies can be explained by the presence of another tumour suppressor gene located at 10q23 (Bostrom et al, 1998; Feilotter et al, 1998; Butler et al, 1999; Saito et al, 2000). This view has been supported by the identification, in several tumour types, of areas of 10q23 deletion distinct from PTEN (Singh et al, 1998a; Yeh et al, 1999). The relatively small number of loci analysed, and the absence of an intragenic marker in our study, raise the possibility that our findings of LOH were related to deletion of another gene at 10q23. However, the close proximity of D10S541 to PTEN (< 0.3 cm) and the higher incidence of D10S541 LOH in our study make it less likely that our findings are due to deletion of another tumour suppressor gene at this locus. Indeed, a high incidence of LOH at D10S541 was noted during fine structure deletion mapping of 10q22–24 in follicular thyroid adenomas and follicular thyroid carcinomas. In this study, LOH at D10S541 appeared to correlate with deletions of the PTEN gene (Yeh et al, 1999).

Other investigators have proposed that PTEN undergoes mechanisms of inactivation other than structural alteration, e.g. somatic mutation. An analysis of prostate cancer xenografts demonstrated decreased levels of both PTEN mRNA and PTEN protein in the absence of PTEN gene mutations (Whang et al, 1998). In this study, treatment with the demethylating agent 5-azadecoxycytidine restored mRNA expression, suggesting that PTEN may undergo inactivation by promoter methylation. Similarly, an analysis of leukaemia and lymphoma cell lines demonstrated decreased levels of PTEN mRNA and PTEN protein, despite the fact that only a small minority of these samples contained PTEN mutations (Dahia et al, 1999). Interestingly, several additional cell lines in this study demonstrated decreased protein levels despite normal or high levels of mRNA, suggesting that PTEN may be inactivated by both transcriptional silencing and by disruption at the protein level. Recently, multiple non-genetic mechanisms of PTEN inactivation have been observed in primary carcinomas of the thyroid, endometrium, cervix, and in melanomas (Gimm et al, 2000; Kurose et al, 2000; Mutter et al, 2000; Zhou et al, 2000).

Analyses of other tumour suppressor genes in oesophageal adenocarcinoma have demonstrated a similar high prevalence of LOH with a corresponding low rate of mutations. The p16 tumour suppressor gene, located on 9p21, encodes a cyclin-dependent kinase inhibitor. Allelic loss of 9p21 has been found in 26–89% of oesophageal adenocarcinomas; however, mutations in p16 are rare (Zhou et al, 1994; Gonzalez et al, 1997; Muzeau et al, 1997). Similarly, allelic loss of 5q has been reported in up to 75% of oesophageal adenocarcinomas, yet mutations of APC have been demonstrated in less than 10% of cases (Boyon et al, 1992; Zhuang et al, 1996; Gonzalez et al, 1997). Many of these tumour suppressor genes, like PTEN, may be regulated by mechanisms other than intragenic mutation. In the case of p16, small homozygous microdeletions appear to be a major mechanism of inactivation, as does methylation of the p16 promoter (Liggett and Sidransky, 1998). Loss of expression of p27, a cyclin-dependent kinase inhibitor, has also been demonstrated in a wide range of malignancies, including oesophageal adenocarcinoma (Esposito et al, 1997; Tan et al, 1997; Singh et al, 1998b; Yang et al, 1998). The expression of p27 appears to be regulated by proteolytic degradation rather than by genetic mutation (Singh et al, 1998b).

LOH at 10q23 in our study did not correlate with any of the clinicopathologic features of the tumours analysed, nor did it correlate with overall survival. These findings contrast with those in breast cancer, where 10q23 LOH has been associated with adverse prognostic factors, including higher stage, higher tumour grade, and loss of oestrogen receptors (Bose et al, 1998; Garcia et al, 1999). In gliomas, the presence of PTEN mutations correlated with high tumour grade (Rasheed et al, 1997; Duerr et al, 1998; Davies et al, 1999; Zhou et al, 1999). However, among high-grade glioblastomas, in which the incidence of PTEN mutation is highest, PTEN mutations do not appear to influence overall survival (Zhou et al, 1999). Given that PTEN may undergo regulation through mechanisms other than somatic mutation, the level of PTEN expression in various malignancies may be a more useful prognostic marker than the presence of PTEN mutation. Indeed, in prostate cancer, loss of PTEN protein expression has been found to be associated with both a high Gleason score and advanced tumour stage, both markers of poor prognosis (McMenamin et al, 1999).

Of the other tumour suppressor genes lost or mutated in oesophageal adenocarcinoma, both p27 and p53 have been analysed with regard to their effect on prognosis. Loss of p27 expression occurs in approximately 80% of BOAaD, and is predictive of a poor prognosis (Singh et al, 1998b). Allelic loss of 17p, the site of the p53 oncogene, is common in oesophageal adenocarcinomas, and p53 mutations have been demonstrated in approximately 50% of cases (Huang et al, 1992; Hamelin et al, 1994; Neshat et al, 1994; Gleeson et al, 1995; Hammoud et al, 1996; Schneider et al, 1996; Dolan et al, 1998). However, p53 mutations do not have any prognostic significance in patients with these tumours (Flejou et al, 1994; Vijeysingam et al, 1994).

In summary, we have demonstrated that, while LOH at 10q23 occurs in a subset of BOAaD, intragenic mutations in the PTEN tumour suppressor gene do not play a significant role in the
development of these lesions. Furthermore, LOH at 10q23 does not correlate with the major clinicopathologic features of these tumours. It is possible that PTEN activity is regulated by mechanisms other than intragenic mutation in BOAD.

REFERENCES

Alimov A, Li C, Gizaftullin R, Fredriksson V, Sundelin B, Klein G and Zabarovsky E (1999) Somatic mutation and homozygous deletion of PTEN/MMAC1 gene at 10q23 in renal cell carcinoma. Anticancer Res 19: 3841–3846

Aveyard J, Skilliter A, Habuchi T and Knowles M (1999) Somatic mutations of PTEN in bladder carcinoma. Br J Cancer 80: 904–908

Bliot W, Devesa S, Knueler R and Fraumeni J (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287–1289

Bose S, Wang S, Terry M, Hibshoosh H and Parsons R (1998) Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17: 123–127

Bostrom J, Cobbers J, Wolter M, Tabatabai G, Weber R, Lichter P, Collins V and Bostrom J, Cobbers J, Wolter M, Tabatabai G, Weber R, Lichter P, Collins V and Collins V (1998) Mutation of the PTEN/MMAC1 tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58: 29–33

Boyrnton R, Blount P, Yin J, Brown W, Huang Y, Tong Y, McDaniel T, Newkirk C, Resau J, Raskind W, Haggit R, Reid B and Meltzer S (1992) Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA 89: 3385–3388

Butler M, Wang S, Chaganti R, Parsons R and Dalla-Favera R (1999) Analysis of PTEN mutations and deletions in B-cell non-Hodgkin lymphomas. Genes Chromosomes Cancer 24: 322–327

Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman J, Jen Isaacs W, Cairns P, Okami K, Halachmi N, Esteller M, Herman J, Bose S, Wang S, Larsen C and Eng C (1997) Somatic deletions and mutations in the PTEN/MMAC1 gene in Cowden disease, an inherited breast and thyroid cancer syndrome. J Clin Pathol 50: 212–217

Chen S, Yu S, Tsai M, Yeh K, Wang J, Kao M, Shih M and Chang J (1999) Mutation analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79: 718–723

Flejou J, Paraf F and Potet F (1994) p53 protein expression in Barrett’s adenocarcinoma: a frequent event with no prognostic significance. Histopathology 24: 487–489

Fleming I, Cooper J and Henson D (1997) AJCC manual for staging of cancer, 5th ed. Berlin, New York: Wiley

Freidhoff D, Kempe A, Beste B, Wappenschmidt B, Kreyer E, Hayashi Y, Meindl A, Krebs D, Wiestler O, Deimling A and Schmutzler R (1999) Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 79: 754–758

Garcia J, Silva J, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, Espada P and Bonilla F (1999) Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57: 427–434

Gasparotto D, Vukosavljevic T, Piccinin S, Barzan L, Sufaro S, Arnellim M, Boiocci M and Maestro R (1999) Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. Int J Cancer 84: 432–436

Gimm O, Perren A, Weng L, Marsh D, Yeh J, Ziebold U, Gil E, Hinze R, Delfride L, Lees J, Robinson B, Komminoth P, Dralle H and Eng C (2000) Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156: 1693–1700

Gleson C, Sloan J and McGuigan J (1995) Base transitions at CpG nucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 55: 3406–3411

Gonzalez M, Artimenez M, Rodrigo L, Lopez-Larrea C, Menendez M, Alvarez V, Perez P, Frenso M, Perez M, Sampedro A and Coto E (1997) Mutation analysis of the p53, APC, and p16 genes in the Barrett’s oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 50: 212–217

Gray I, Stewart L, Phillips S, Hamilton J, Gray N, Watson G, Spurr N and Snary D (1998) Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 78: 1296–1300

Gronbaek Y, Zeuthen J, Goldberg P, Ralfkiaer E and Hou-Jensen K (1998) Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood 91: 4388–4390

Goldberg P, Straten P, Birck A, Ahrenkild V, Kirkin A and Zeuthen J (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent even in malignant melanoma. Cancer Res 57: 3660–3663

Hamelin R, Flejou J and Muzeau F (1994) TP53 gene mutations and p53 protein immuno-reactivity in malignant and premalignant Barrett’s oesophagus. Gastroneterology 107: 1012–1018

Hammoud Z, Kaleem Z, Cooper J, Sundaresan R, Patterson G and Goodfellow P (1996) Allelotyping analysis of esophageal adenocarcinomas: evidence for involvement of sequences on the long arm of chromosome 4. Cancer Res 56: 4499–4502

Huang Y, Boyrenton R, Blount P, Silverstein R, Yin J, Tong Y, McDaniel T, Newkirk C, Resau J, Sridhar R, Reid B and Meltzer S (1992) Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 52: 6525–6530

Hokuno T, Takahashi M, Manda R and Yokota J (1998) Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosom Cancer 22: 152–156

Kong D, Suzuki A, Zou T, Sakurada A, Kemp L, Watanakunuk E, Yokoyama T, Yamakawa H, Fukusawa T, Tago M, Ohuchi N, Sato S, Yin J, Wang S, Abraham J, Souza R, Smolinski K, Meltzer S and Horii A (1997) PTEN1 is frequently mutated in primary endometrial carcinomas. Nature Genet 17: 143–144

Kurose K, Zhou H, Araki T and Eng C (2000) Biallelic inactivating mutations and a occult germline mutation of PTEN in primary cervical carcinomas. Gene Chromosom Cancer 29: 166–172

Lagerrgen J, Bergstrom R, Lindgren A and Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825–831

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S, Puc J, Miliaresis C, Rodgers L, MCombire R, Bigner S, Giovannella B, Ittmann M, Tycko B, Hibshoosh H, Wigler M and Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 64–67

Liggett W and Sidransky D (1998) Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197–1206
Liu W, James D, Frederick L, Aldrete B and Jenkins R (1997) PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. *Cancer Res* 57: 5254–5257

Maier D, Zhang Z, Taylor E, Hamou M, Gratzi O, Meir E, Scott R and Merlo A (1998) Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25–26 region as the primary target in low-grade and high-grade gliomas. *Oncogene* 16: 551–5555

Marsh D, Daiha P, Zheng Z, Liaw D, Parsons R, Gorlin R and Eng C (1997a) Germline mutations in PTEN are present in Bannayan-Zonana syndrome. *Nature Genet* 16: 333–334

Marsh D, Roth S, Lunetta K, Hemminki A, Daiha P, Sistonen P, Zheng Z, Caron S, Orosou N, Bodmer W, Cottrell S, Dunlop M, Eccles D, Hodgson S, Jarvinen H, Kellokumpu I, Markie D, Neale K, Phillips R, Rozen P, Syngal S, Vigg J, Tomlinson I, Aalktonen L and Eng C (1997b) Exclusion of PTEN and 10q22–24 as the susceptibility locus for juvenile polyposis syndrome. *Cancer Res* 57: 5017–5021

Marsh D, Daiha P, Caron S, Kum J, Frayling I, Tomlinson I, Hughes K, Eeles R, Hodgson S, Murday V, Houlston R and Eng C (1998) Germline PTEN mutations in Cowden syndrome-like families. *J Med Genet* 35: 881–888

Marsh D, Kum J, Lunetta K, Bennett M, Gorlin R, Ahmed S, Bodurtha J, Crowe C, Curtis M, Dasouki M, Dunn T, Feit H, Geraghty M, Graham J, Hodgson S, Hunter A, Korf B, Manchester D, Miesfeldt S, Murday V, Nathanson K, Parisi M, Pober B, Romano C, Tolmie J, Trebath R, Winter R, Zacka E, Zori R, Weng L, Daiha P and Eng C (1999) PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single gene with Cowden syndrome. *Hum Mol Genet* 8: 1461–1472

McKenamin M, Soung P, Perera S, Kaplan I, Loda M and Sellers W (1999) Loss of *p27* in Barrett’s associated adenocarcinoma. *Cancer Res* 59: 4291–4296

Mutter G, Lin M, Fitzgerald J, Kum J, Baak J, Lees J, Weng L and Eng C (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. *J Natl Cancer Inst* 92: 924–931

Muzeau F, Flejou J, Thomas T and Hamelin R (1997) Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers. *Int J Cancer* 72: 27–30

Myers M, Stoliarov J, Eng C, Li J, Wang S, Wigler M, Parsons R and Tonks N (1997) PTEN, the tumor suppressor from human chromosome 10q23, is a dual specificity phosphatase. *Proc Natl Acad Sci (USA)* 94: 9052–9057

Nakahara Y, Nagai H, Kinoshita T, Uchida T, Hatano S, Murate T and Saito H (1998) Rasheed B, Stenzel T, McLendon R, Parsons R, Friedman A, Friedman H, Bigner D and Bigner S (1997) PTEN gene mutations are seen in high grade but not in low-grade gliomas. *Int J Cancer* 71: 150–154

Neshat K, Sanchez C and Galipeau P (1994) *p53* mutations in Barrett’s esophagus and Barrett’s cancer: a prospective study of ninety-eight cases. *Cancer Res* 54: 157–160

Okami K, Wu L, Riggins G, Cairns P, Sidransky D, Isaacs W and Eng C (1997) PTEN/MMAC1 point to the 10q25–26 region as the primary target in low-grade and high-grade gliomas. *Oncogene* 16: 2879–2883

Peterman S, Rudolf J, Bockmuhl U, Gellert K, Wolf G, Dietel M and Petersen I (1998) Distinct regions of allelic imbalance on chromosome 10q22–q26 in squamous cell carcinomas of the lung

Rasheed B, Stenzel T, McLendon R, Parsons R, Friedman A, Friedman H, Bigner D and Bigner S (1997) PTEN gene mutations are seen in high grade but not in low-grade gliomas. *Cancer Res* 57: 4187–4190

Risinger J, Hayes A, Berchuk A and Barrett J (1997) PTEN/MMAC1 mutations in endometrial cancers. *Cancer Res* 57: 4736–4738

Saito M, Okamoto A, Kobito T, Takakura S, Shinozaki H, Isonishi S, Yasuhara T, Yoshimura T, Ohtake Y, Ochiai K, Yokota J and Tanaka T (2000) Allelic imbalance and mutations of the PTEN gene in ovarian carcinoma. *Int J Cancer* 85: 160–165

Sakai A, Theilebont C, Wellmann A, Jaffe E and Raffeloff M (1999) PTEN gene alterations in lymphoid neoplasms. *Blood* 92: 3410–3415

Schneider P, Casson A, Levin B, Houlston R, Hoelscher A, Becker K, Dittler H, Cleary M, Schilder S, Chiaro D, Pagano M and Loda M (1998) Loss or altered subcellular localization of p27 in Barrett’s associated adenocarcinoma. *Cancer Res* 58: 1730–1735

Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A, Langford L, Baumgard M, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng D and Tavtigan S (1997) Identification of a candidate tumor suppressor gene, MAC1C, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nature Genet* 15: 356–362

Suzuki H, Freije D, Nusskern D, Okami K, Cairns P, Sidransky D, Isacs W and bova G (1998) Interfacial heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. *Cancer Res* 58: 204–209

Tan P, Cady B, Wanner M, Worland P, Cukor B, Magli-Galluzzo C, Lavin D, Pretta D, Gagana P, Loda M and Loda M (1997) The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. *Cancer Res* 57: 1259–1263

Tashiro H, Blazes M, Wu R, Cho K, Bosse W, Simg W, Li J, Parsons R and Ellenson L (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. *Cancer Res* 57: 3935–3940

Teng D, Hu R, Lin D, Davis T, Iliev D, Frye C, Swedlund B, Hansen K, Vinson V, Gumper K, Ellis L, El-Neaggar A, Frazer M, Jasser S, Langford L, Lee I, Mills G, Pershouse M, Pollack R, Tornos C, Trucco P, Yang W, Fujii G, Berson A, Bookstein R, Bolens J, Tavtigan S and Steck (P) (1997) PTEN/MMAC1 mutations in primary tumor specimens and cell lines. *Cancer Res* 57: 5221–5225

Tsao H, Zhang X, Benoit E and Hulskus F (1998) Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. *Oncogene* 16: 3397–3402

Vijayasingram R, Darston S, Jenner K, Allen C, Billingham C and Matthews H (1994) Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. *Br J Surg* 81: 1623–1626

Wang S, Pue C, Ji L, Bruce J, Cairns P, Sidransky D and Parsons R (1997) Somatic mutations of PTEN in glioblastoma multiforme. *Cancer Res* 57: 4183–4186

Whang Y, Wu X, Suzuki H, Reiter R, Tran C, Vessalla S, Said J, Isacs W and Sawyer C (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. *PNAS* 95: 5246–5250

Yagumura Y, Yamashita T, Ichiya T, Morizaki A, Kato Y, Takahashi T, Hayashi H and Ishikawa M (2000) Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers. *Molecular Carcinogenesis* 27: 110–116

Yang R, Naito J, Murphy M, Wang H, Phillips J, deKernion J, Loda M and Reiter R (1998) Low p27 expression predicts poor disease-free survival in patients with prostate cancer. *J Urol* 159: 941–945

Yeh I, Marsh D, Zedernius I, Dwight T, Delbridge L, Robinson B and Eng C (1999) Fine-structure deletion mapping of 10q22–24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. *Genes Chromosomes Cancer*

Yokomizo T, Dirdall D, Drabkin H, Gemmill R, Franklin W, Yang P, Sugio K, Smith D and Liu W (1998) PTEN/MMAC1 mutations identified in small cell lung cancers, but not in small non-cell lung cancers. *Oncogene* 17: 475–479

Zhuang Z, Vortmeyer A, Mark E, Odze R, Emmert-Buck M, Merino M, Moon H, Lotta L, Kashi K and Duray P (1996) Barrett’s esophagus: metaplastic lesions with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. *Cancer Res* 56: 1961–1964

© 2001 Cancer Research Campaign British Journal of Cancer (2001) 84(6), 748–753